AbCellera Biologics (ABCL) Climbs +76% Over 30 Days on Phase 2 Data
Key Takeaways
- AbCellera Biologics shares gained approximately 76% over the 30-day period through the latest available close, rising from $6.47 on July 17, 2026, to $11.38 on August 14, 2026.
- The decisive catalyst was positive Phase 2 data for ABCL635, an investigational antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause.
- A roughly $200 million follow-on equity offering and a new T-cell engager collaboration with Vertex Pharmaceuticals (VRTX) strengthened the company's funding position and platform validation.
- Second-quarter revenue declined year over year and the net loss widened, but investors focused on pipeline progress and the company's extended cash runway.
- Over the trailing quarter, the stock rose roughly 181% from the May 19, 2026 close of $4.05, reflecting a powerful but volatile multi-month uptrend.
Company Overview: AbCellera Biologics and Its Market Position
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines. Its platform combines technology, data science, infrastructure, and interdisciplinary teams to address challenging antibody discovery problems across endocrinology, women's health, immunology, oncology, and other therapeutic areas.
The company's most advanced internal programs include ABCL635, an antibody candidate for vasomotor symptoms associated with menopause, and ABCL575, an antibody candidate with potential applications in inflammatory and autoimmune conditions. AbCellera also licenses its T-cell engager platform to partners and has built a pipeline of internal discovery programs. Investors follow the stock for its clinical readouts, partnership economics, and the potential for milestone and royalty revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ABCL Stock Performance: The Last 30 Days Versus the Quarter
Over the last 30 days, ABCL moved from a closing price of $6.47 on July 17, 2026, to $11.38 on August 14, 2026, a gain of approximately 76%. The move was concentrated in mid-August, with daily trading volume expanding sharply as clinical data and financing news reached the market.
The trailing-quarter trend is even stronger. From the May 19, 2026 close of $4.05 to the August 14, 2026 close of $11.38, the stock rose roughly 181%. The path was not linear: shares climbed to $8.12 by June 29, pulled back to $5.31 by July 24, and then surged following the ABCL635 Phase 2 readout. From what I see, the volatility highlights both the risks and the momentum in this name.
Key Catalysts Behind the Recent 30-Day Gains
The primary catalyst was the Phase 2 readout for ABCL635. The company reported that the antibody reduced hot flash frequency by 83% in a study of 92 postmenopausal women, compared with a 33% reduction in the placebo group. Severity scores improved by 58% versus 12% for placebo, and the safety profile was generally favorable, with headache, fatigue, and injection-site reactions among the most common adverse events.
The data triggered analyst repricing. Truist Securities raised its price target to $30 from $12, Cantor Fitzgerald lifted its target to $12 from $11, Stifel increased its target to $9 from $8, and Piper Sandler initiated coverage with a buy rating, according to published analyst notes.
Funding and partnership news amplified the move. AbCellera completed a roughly $200 million follow-on equity offering and announced a collaboration with Vertex Pharmaceuticals (VRTX) to develop multispecific T-cell engagers for autoimmune diseases, with Vertex paying $28 million upfront and funding research and development costs. These developments addressed balance-sheet concerns while adding a new platform partnership.
Drivers Behind the Stronger Quarterly Performance
The quarterly trend reflects a broader shift in the investment narrative from partnership-driven revenue toward internal clinical assets. In June, AbCellera announced a T-cell engager collaboration with Jazz Pharmaceuticals (JAZZ) for gastrointestinal cancers and other solid tumors, including $56 million in upfront payments for the first two programs and up to $792 million per program in potential milestones.
After a mid-summer pullback that took shares below $5.50 in late July, the August ABCL635 data, the Vertex agreement, and the equity offering restored upward momentum. The move also reflected increased investor attention on the company's women's health opportunity and its ability to generate non-dilutive funding through platform deals. One thing that stands out is how quickly sentiment shifted once the clinical and partnership pieces aligned.
What to Watch Next for ABCL
The most important upcoming factors for ABCL include additional ABCL635 data, regulatory planning, and the company's ability to advance the program toward late-stage development. Management has identified a large addressable population, with roughly 12 million women in the United States experiencing moderate-to-severe vasomotor symptoms and more than six million seeking treatment, according to company estimates.
Other watch items include top-line Phase 1 data for ABCL575 expected in the fourth quarter of 2026, progress on ABCL688 and ABCL386 through IND-enabling activities, and the advancement of T-cell engager programs with Vertex Pharmaceuticals (VRTX) and Jazz Pharmaceuticals (JAZZ). Investors should also monitor cash runway, clinical and regulatory risk, placebo response in vasomotor symptom studies, revenue lumpiness, competitive dynamics, and broader biotechnology sector sentiment. I’m watching this closely as the next data points could further clarify the trajectory.
Using AI Tools for Market Insights
In my view, tools like Tickeron’s AI Trend Prediction Engine can add useful context when evaluating momentum in names such as ABCL. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. These resources help surface patterns that might otherwise go unnoticed in fast-moving sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ABCL sees MACD Histogram crosses below signal line
ABCL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 31, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 37 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABCL moved out of overbought territory on September 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 21 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
ABCL broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on ABCL as a result. In 74 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +11.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 205 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 118 of 155 cases where ABCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.568) is normal, around the industry mean (25.929). P/E Ratio (11.976) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (437.043).
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement